Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD9496 in Women With Estrogen Receptor Positive HER-2 Negative Advanced Breast Cancer

NCT02248090 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02248090
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02248090 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD9496 in Women With Estrogen Receptor Positive HER-2 Negative Advanced Breast Cancer
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
October 22, 2014
Completion date
April 3, 2019
Enrollment
45 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

er+ her2- advanced breast cancer